Protypia was founded in 2017 by Dan Liebler to bring emerging mass spectrometry (MS) proteomics technology to oncology therapeutic discovery and development.
Protypia has worked with a growing roster of leading pharmaceutical and biotechnology companies in oncology, autoimmune disease, and gene editing therapeutics.
Protypia also works with leading academic collaborators to advance the application of MS protein analysis to identify therapeutic targets and protein features that govern drug resistance and response.
Protypia is now part of Inotiv, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models. Protypia technology and expertise is synergistic with Inotiv’s extensive discovery services offering, enhancing its ability to support clients in the development of safe and effective drugs. More information about Protypia’s services can be found at our Proteomics page.
Enabling better therapeutics with proteomic technology
Protypia, now a part of Inotiv, provides a targeted proteomics platform to precisely quantify drug target systems in cells, tissue models and human tissues, directly integrating protein-level pharmacology and pathology across multiple therapeutic areas, supporting multiple therapeutic modalities from discovery through clinical development.
To learn more about the acquisition, read our news release.
Genetic Toxicology
Toxicogenomics
General Toxicology
Histology
Pathology
